Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study

NCT06598527 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

RADIATION: Stereotactic body radiotherapy (SBRT)
DRUG: Tislelizumab
DRUG: Chemotherapy

Sponsor

Yang Hong